Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $85.25 Average Price Target from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the four ratings firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $85.25.

PBH has been the topic of a number of analyst reports. StockNews.com lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Monday. Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Jefferies Financial Group restated a "hold" rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Sidoti cut Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Finally, DA Davidson reissued a "buy" rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th.

Insiders Place Their Bets

In related news, SVP Mary Beth Fritz sold 9,885 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the transaction, the senior vice president now directly owns 18,835 shares in the company, valued at $1,543,904.95. This trade represents a 34.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Adel Mekhail sold 9,063 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares of the company's stock, valued at $1,505,930. The trade was a 33.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 over the last 90 days. Insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PBH. Quest Partners LLC grew its stake in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company's stock worth $30,000 after purchasing an additional 424 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock worth $35,000 after buying an additional 433 shares during the period. nVerses Capital LLC grew its position in shares of Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company's stock worth $43,000 after buying an additional 400 shares during the last quarter. Huntington National Bank increased its stake in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after buying an additional 181 shares during the period. Finally, International Assets Investment Management LLC raised its holdings in shares of Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company's stock valued at $83,000 after acquiring an additional 1,138 shares in the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH traded down $0.84 during trading on Friday, hitting $76.88. 288,543 shares of the company were exchanged, compared to its average volume of 301,422. The company has a market cap of $3.80 billion, a PE ratio of 18.71, a P/E/G ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare has a 52-week low of $57.95 and a 52-week high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The stock has a 50 day moving average of $80.50 and a 200 day moving average of $73.94.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same quarter last year, the company earned $1.07 EPS. The firm's revenue was down .9% compared to the same quarter last year. As a group, equities research analysts predict that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.